🚀 VC round data is live in beta, check it out!
Star Lake Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Star Lake Bioscience and similar public comparables like Innoviva, Sarepta Therapeutics, ANI Pharmaceuticals, RAPT Therapeutics and more.
Star Lake Bioscience Overview
About Star Lake Bioscience
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
Founded
1992
HQ
Employees
2.7K
Website
Financials (FY)
EV
$2B
Star Lake Bioscience Financials
Star Lake Bioscience reported last fiscal year revenue of $2B and EBITDA of $315M.
In the same fiscal year, Star Lake Bioscience generated $428M in gross profit, $315M in EBITDA, and $136M in net income.
Revenue (LTM)
Star Lake Bioscience P&L
In the most recent fiscal year, Star Lake Bioscience reported revenue of $2B and EBITDA of $315M.
Star Lake Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $428M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA | — | XXX | $315M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 9% | XXX | XXX | XXX |
| Net Profit | — | XXX | $136M | XXX | XXX | XXX |
| Net Margin | — | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $139M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Star Lake Bioscience Stock Performance
Star Lake Bioscience has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Star Lake Bioscience's stock price is $1.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStar Lake Bioscience Valuation Multiples
Star Lake Bioscience trades at 0.8x EV/Revenue multiple, and 6.7x EV/EBITDA.
EV / Revenue (LTM)
Star Lake Bioscience Financial Valuation Multiples
As of March 18, 2026, Star Lake Bioscience has market cap of $2B and EV of $2B.
Equity research analysts estimate Star Lake Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Star Lake Bioscience has a P/E ratio of 12.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 8.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.9x | XXX | XXX | XXX |
| P/E | — | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 8.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Star Lake Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Star Lake Bioscience Margins & Growth Rates
Star Lake Bioscience's revenue in the last fiscal year declined by (0%).
Star Lake Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Star Lake Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Innoviva | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarepta Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| RAPT Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| AnaptysBio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Star Lake Bioscience M&A Activity
Star Lake Bioscience acquired XXX companies to date.
Last acquisition by Star Lake Bioscience was on XXXXXXXX, XXXXX. Star Lake Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Star Lake Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStar Lake Bioscience Investment Activity
Star Lake Bioscience invested in XXX companies to date.
Star Lake Bioscience made its latest investment on XXXXXXXX, XXXXX. Star Lake Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Star Lake Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Star Lake Bioscience
| When was Star Lake Bioscience founded? | Star Lake Bioscience was founded in 1992. |
| Where is Star Lake Bioscience headquartered? | Star Lake Bioscience is headquartered in China. |
| How many employees does Star Lake Bioscience have? | As of today, Star Lake Bioscience has over 2K employees. |
| Is Star Lake Bioscience publicly listed? | Yes, Star Lake Bioscience is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Star Lake Bioscience? | Star Lake Bioscience trades under 600866 ticker. |
| When did Star Lake Bioscience go public? | Star Lake Bioscience went public in 1994. |
| Who are competitors of Star Lake Bioscience? | Star Lake Bioscience main competitors are Innoviva, Sarepta Therapeutics, ANI Pharmaceuticals, RAPT Therapeutics. |
| What is the current market cap of Star Lake Bioscience? | Star Lake Bioscience's current market cap is $2B. |
| What is the current revenue of Star Lake Bioscience? | Star Lake Bioscience's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of Star Lake Bioscience? | Current revenue multiple of Star Lake Bioscience is 0.8x. |
| Is Star Lake Bioscience profitable? | No, Star Lake Bioscience is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.